Figure 6: Combined treatment with tivozanib and erlotinib results in anti-proliferative and pro-apoptotic synergism. | Scientific Reports

Figure 6: Combined treatment with tivozanib and erlotinib results in anti-proliferative and pro-apoptotic synergism.

From: Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells

Figure 6

(A) The effect of the time-sequenced tivozanib-erlotinib therapy on cell proliferation was investigated by MTT assay and shown by IC50 shift analysis. (B) Normalised isobolograms of combination of tivozanib (10 μM) and erlotinib (1, 2, 5, 10, 20 and 50 μM). The data were analysed using the CalcuSyn software. The connecting line represents additivity. Data points located below the line indicate a synergistic drug-drug interaction and data points above the line indicate an antagonistic drug-drug interaction. The numbers under the isobolograms indicate the doses of tivozanib and erlotiinb in combination (C) The effect of combined tivozanib-erlotinib treatment on activation of caspase 3 was measured by a colorimetric caspase 3 activity assay. Data are given as mean ± SD. Statistically significant values of *p < 0.05, **p < 0.01, and ***p < 0.001 were determined compared with the control.

Back to article page